Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $50

Ascendiant Capital analyst Edward Woo has maintained a Buy rating on NRX Pharmaceuticals (NASDAQ: NRXP) and increased the price target from $49 to $50.